Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Veliparib

Veliparib

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Veliparib

20 trials tracked of Veliparib: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 323 citations.

20Trials tracked
2Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 2 Phase 2 17 Phase 1 1
  1. Phase 3 A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer Completed · 323 cited
  2. Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers Completed · 30 cited
  3. Phase 2 Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Completed
  4. Phase 2 Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer Completed
  5. Phase 2 Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Completed
  6. Phase 2 Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer Completed
Show 14 more trials
  1. Phase 2 Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer Completed
  2. Phase 2 Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer Completed
  3. Phase 2 Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer Completed
  4. Phase 2 Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed
  5. Phase 2 Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer Completed
  6. Phase 2 FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer Completed
  7. Phase 2 Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases Completed
  8. Phase 2 Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer Completed
  9. Phase 2 Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer Completed
  10. Phase 2 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed
  11. Phase 2 Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer Completed
  12. Phase 2 Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas Completed
  13. Phase 2 MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations Completed
  14. Phase 1 Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma Completed

Showing the 20 most-cited and recently-updated of 20 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Platinum agents, PARP inhibitors, and immune checkpoint inhibitors increase pCR rates in early-stage TNBC
OB/GYN & Women's Health Sys. Review
Platinum agents, PARP inhibitors, and immune checkpoint inhibitors increase pCR rates in early-stage TNBC New data shows specific drug combinations improve triple-negative breast cancer outcomes
This network meta-analysis of 7,683 patients with early-stage triple-negative breast cancer (TNBC) evaluated various neoadjuvant treatment r…
New data shows that adding specific drugs like pembrolizumab or bevacizumab to standard chemotherapy can improve response rates for early-st…
Sep 1, 2026
Olaparib, rucaparib, and niraparib significantly improve progression-free survival across age groups in advanced ovarian cancer
Oncology Meta-analysis
Olaparib, rucaparib, and niraparib significantly improve progression-free survival across age groups in advanced ovarian cancer PARP Inhibitors Show Improved Survival for Advanced Ovarian Cancer
This network meta-analysis of randomized trials evaluates PARP inhibitors for advanced ovarian cancer. The analysis indicates that olaparib,…
New data shows PARP inhibitors like olaparib and niraparib may improve survival for both younger and older patients with advanced ovarian ca…
Frontiers Jul 9, 2026